Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, Alexander Reuß, Andrés Redondo, Kristina Lindemann, Christian Kurzeder, Edgar Petru, Florian Heitz, Jalid Sehouli, N deGregorio, Pauline Wimberger, Alexander Burges, Nadin Cron, Jonathan A. Ledermann, Domenica Lorusso, Xavier Paolettí, Frederik Marmé
Topics & Concepts
BevacizumabMedicineAtezolizumabChemotherapyOvarian cancerOncologyRandomized controlled trialInternal medicineCancerImmunotherapyPembrolizumabOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers